Evidence map›Paper›PMID 37425776›Full record

ArticlebioRxiv : the preprint server for biology2023

Unique vulnerability of

Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison M Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Alexa C CannonCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA.
Konstantin BudagyanCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA.
Cristina Uribe-AlvarezCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA.
Alison M KurimchakCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA.
Daniela Araiza-OliveraCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA.
Kathy Q CaiHistopathology Facility, Fox Chase Cancer Center, Philadelphia, PA.
Suraj PeriBiostatistics-Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA.
Yan ZhouBiostatistics-Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA.
James S DuncanCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA.
Jonathan ChernoffCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA.
Fox Chase Cancer Center · USMerck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Dietmar J Kappes · 1985 to 2026
$138.8M
TRAINING PROGRAM IN CANCER RESEARCHT32CA009035 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN · 1985 to 2020
$10.5M
Targeting the Rac1 signaling pathway in malignant melanomaR01CA227184 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN · 2018 to 2022
$2.5M
Targeting the kinome in K-ras driven colorectal cancersR01CA211670 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI DUNCAN, JAMES STUART · 2017 to 2021
$2.1M
NCI NIH HHS P30 CA006927NCI NIH HHS R01 CA211670NCI NIH HHS R01 CA227184NCI NIH HHS T32 CA009035
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37425776
PMCPMC10327161
OpenAlexW4382362003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.